EIRLOOM x AKADEMIKLINIKEN
The revenue case for Akademikliniken
The partnership
AK brings surgical expertise, the procedure itself, decades of technical skill. Eirloom brings what happens around it, the sustained daily change in fitness, nutrition, sleep and stress that determines how well a patient arrives at surgery and how fully they recover from it. Neither replaces the other, and together they cover the whole journey a patient actually goes through.
AK could become the first surgical group in the world to send patients into surgery measurably stronger and bring them out of it measurably faster, and generate a new revenue line by doing it. A share of every program fee, booked inside a consultation AK is already having. Then a share of the revenue from every patient who becomes an Eirloom client afterwards, paid every year that client stays.
What one patient is worth to AK
| Patient path | Program share | Client share, yr 1 | Total, yr 1 | Two year total |
|---|---|---|---|---|
| Track A, upgrades to Track B, becomes an Eirloom client | 4,500 | 13,048 | 17,548 | 30,596 |
| Track B directly, becomes an Eirloom client | 4,000 | 13,048 | 17,048 | 30,096 |
| Track A, upgrades to Track B, stops after recovery | 4,500 | 0 | 4,500 | 4,500 |
| Track B directly, stops after recovery | 4,000 | 0 | 4,000 | 4,000 |
| Track A, does not upgrade | 1,100 | 0 | 1,100 | 1,100 |
- Track A is the biomarker introduction offer. It gives the patient their biomarker results and an assessment tailored to their surgery
- Track B is the full program, eight to ten weeks of preparation before surgery and eight to ten weeks of recovery support after it
- A patient who upgrades pays 5,500 for the diagnostic, then 17,000 for the program, a 3,000 credit against what they already paid
- Stopping after recovery earns AK 4,000 to 4,500 once. Continuing as an Eirloom client earns AK more than 30,000
AK surgical footprint
| Market | Surgical clinics | Surgeries / yr * | Program launch |
|---|---|---|---|
| Sweden | 3 | 3,000 | Q4 2026 pilot |
| Denmark | 2 | 2,000 | Q2 2027 |
| Norway | 1 | 1,000 | Q2 2027 |
| Total | 6 | 6,000 |
- Only clinics that perform surgery are counted. Skin Center locations are excluded
- * Surgery volumes are Eirloom's working estimate, not AK figures. AK's own surgical numbers would replace these
Patients through the program
| Period | Patients | % of surgeries | Track A | Upgrade, 75% | Track B | New clients, 35% | Paying clients |
|---|---|---|---|---|---|---|---|
| Pilot, Q4 2026 | 20 | 0.7% | 12 | 9 | 17 | 6 | 0 |
| Year 1, 2027 | 435 | 7.2% | 261 | 196 | 370 | 129 | 135 |
| Year 2, 2028 | 990 | 16.5% | 594 | 446 | 842 | 295 | 430 |
| Year 3, 2029 | 1,410 | 23.5% | 846 | 634 | 1,198 | 419 | 714 |
| Year 4, 2030 | 1,500 | 25.0% | 900 | 675 | 1,275 | 446 | 865 |
| Year 5, 2031 | 1,710 | 28.5% | 1,026 | 769 | 1,454 | 509 | 955 |
- Both tracks are offered side by side at consultation, so there is no second sale to make later
- Three quarters of Track A patients upgrade once their biomarker results come back
- Paying clients are this year's joiners plus last year's, who are still paying. The pilot's clients finish recovery in early 2027, so they begin paying in Year 1
- Penetration climbs to a quarter of surgical patients by Year 3 and keeps building gradually from there, on the strength of results rather than a harder sell
AK revenue
| Period | Program share | Client share | AK total | Growth |
|---|---|---|---|---|
| Pilot, Q4 2026 | 75,800 | 0 | 75,800 | |
| Year 1, 2027 | 1,648,650 | 1,761,507 | 3,410,157 | |
| Year 2, 2028 | 3,752,100 | 5,610,726 | 9,362,826 | +175% |
| Year 3, 2029 | 5,343,900 | 9,316,415 | 14,660,315 | +57% |
| Year 4, 2030 | 5,685,000 | 11,286,693 | 16,971,693 | +16% |
| Year 5, 2031 | 6,480,900 | 12,461,031 | 18,941,931 | +12% |
| Cumulative to AK | 22,986,350 | 40,788,673 | 63,422,722 |
- Program share is 20 percent of every fee booked, paid at booking
- Client share is 15 percent of subscription revenue, paid every year the client stays
- The client share passes the program share in Year 2 and never gives the lead back
- By Year 4 AK is earning roughly 17 million a year, the annual contribution of a fourth Swedish surgical clinic, without building one, and it is still growing
The patients who come back
This is the part that does not appear in the table above. An Eirloom client stays in an ongoing health relationship for two years after their surgery, which gives AK a natural, warm way to remain part of that patient's journey. If even a modest share return for a second procedure, the value adds up. Applied to the 714 paying clients in Year 3:
| If this share returns | Procedures | AK surgery revenue | Marketing cost avoided |
|---|---|---|---|
| 5 percent | 36 | 2,160,000 | 180,000 |
| 10 percent | 71 | 4,260,000 | 355,000 |
| 15 percent | 107 | 6,420,000 | 535,000 |
- Surgery revenue at AK's own full margin, not a share of anything
- A returning patient costs nothing to reacquire, so the marketing saved falls straight through
- Both figures are Eirloom estimates. AK's real acquisition cost would sharpen this considerably
Why this revenue lasts
This revenue is durable in a way advertising is not. Rules for aesthetic procedures have tightened since 2021, IVO has supervised the sector since 2023, and further restriction is under consideration. Clinical outcome data is the one form of marketing that gets easier to use as the rules get harder. This builds that asset while producing revenue.
Scenario range, AK total
| Scenario | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | 5 yr total |
|---|---|---|---|---|---|---|
| Conservative | 2,245,960 | 6,105,409 | 9,527,900 | 11,041,387 | 12,315,517 | 41.3M |
| Base | 3,410,157 | 9,362,826 | 14,660,315 | 16,971,693 | 18,941,931 | 63.4M |
| Optimistic | 4,587,402 | 12,620,243 | 19,792,730 | 22,915,048 | 25,568,345 | 85.6M |
- Only penetration flexes, reaching 19 to 39 percent of surgical patients by Year 5
- Pricing, upgrade rate, conversion rate and client life hold constant across all three
Key assumptions
| Assumption | Parameter | Operational rationale |
|---|---|---|
| Surgeries per surgical clinic * | 1,000 / yr | Eirloom estimate, 3,000 across 3 Swedish sites |
| Penetration of surgeries, Sweden | 10 / 18 / 25 / 29% | Years 1 through 5, continuing to build |
| Penetration, Denmark and Norway | 6 / 15 / 22 / 28% | Staggered launch from Q2 2027, continuing to build |
| Track A fee, biomarker intro | 5,500 SEK | Biomarker panel plus a surgery targeted assessment |
| Track B fee, full program | 20,000 SEK | 8 to 10 wks prehab, 8 to 10 wks recovery |
| Upgrade credit | 3,000 SEK | Track B costs 17,000 for a Track A patient |
| AK program share | 20% | Paid on every fee booked, both tracks |
| Entry mix, Track A vs Track B | 60 / 40 | Offered side by side at consultation |
| Track A upgrades to Track B | 75% | Biomarker findings drive the conversation |
| Track B becomes an Eirloom client | 35% | Continuation once recovery ends |
| Client mix, Core vs Elite | 75 / 25 | 4,999 and 13,999 SEK per month |
| Blended client annual value | 86,988 SEK | Paid upfront on joining |
| Client stays | 2 years | Then leaves the model entirely |
| AK client share | 15% | Every year the client pays |
| Avg AK procedure value * | 60,000 SEK | Eirloom estimate, returning patient table only |
| AK patient acquisition cost * | 5,000 SEK | Eirloom estimate from 8 to 12% marketing benchmark |